Laparoscopic cryoablation (LCA) of renal masses is associated with excellent long-term renal functional outcomes and cancer-specific survival, according to researchers.
A team at Washington University School of Medicine in St. Louis, Mo., reviewed data from 62 patients who underwent LCA at their institution. The mean estimated glomerular filtration rate (eGFR) preoperatively and at last follow-up was 68.3 and 64.5 mL/min/1.73 m2, respectively, a nonsignificant difference.
Among patients with biopsy-proven, localized renal cell carcinoma, the six-year Kaplan-Meier estimated disease-free, cancer-specific, and overall survival were 80%, 100%, and 76.2%, respectively, the investigators reported in Urology (2012;80:307-315). The mean follow-up in this subset of patients was 76 months.
Among patients who experienced cancer recurrence, the mean time to recurrence was 27.6 months. A tumor size of 2.6 cm or greater was the only predictor of cancer recurrence. Patients with tumors of this size were nearly 29 times more likely to experience recurrence than patients with smaller tumors.
The researchers, led by R. Sherburne Figenshau, MD, said their study is the longest follow-up to date of postlaparoscopic cryoablation chnges in eGFR.
Study subjects had a perioperative complication rate of 9.7% and mean estimated blood loss of 84.9 mL.